Radiopharmaceutical Consulting Support

We consult with clients on a range of radiopharmaceutical programs, and routinely advise investors and BD teams on individual assets, pipelines and companies. Our core team draws from our extended consulting network, containing highly-experienced consultants who bring significant experience in radiopharmaceuticals, allowing us to field project teams that precisely matches your needs.

The support we provide ranges from opportunity mapping and business strategy to regulatory affairs, preclinical and clinical support, to due diligence, valuations and licensing, partnering & dealmaking.

For more information on our capabilities, please reach contact us.

Recent Radiopharmaceutical Projects:


  • Assessing the radiopharma landscape, future demand and competitive dynamics: A radiopharmaceuticals CDMO with activities in a range of therapeutic and diagnostic compounds including development-stage and commercial products asked Alacrita to assess the landscape and project future demand and the competitive dynamics in the field. 

  • Immunotherapy strategy for a radiotherapy company: A major player in the radiation oncology market was looking for growth opportunities and had identified cancer immunotherapy as a potential opportunity, given the increasing evidence that radiation can synergize with immunotherapy. We were asked to develop a strategy and business plan.

  • Landscape analysis of the radiopharma market: A VC investor considering funding a radiopharmaceutical company requested an analysis of the therapeutic radiopharmaceutical landscape, to help them evaluate the investment. The purpose of the exercise was to identify where the greatest opportunity may lay for molecular targeted radiotherapy (MTR). The analysis was to focus on three specific areas:
    • Why there may be an opportunity for MTRs in the current landscape;
    • Size and growth of the potential market; and
    • Competitive landscape, including current pipelines and products being developed.
  • Radiopharma R&D strategy for nuclear physics research institute: A major nuclear physics research institute looking to build a capability in nuclear medicine needed support with its R&D plan. Led by a consultant with more than 25 years’ experience in nuclear medicine R&D and business development, our radiopharmaceuticals consulting team developed an R&D strategy.

  • Medical and technical support for a European pharmaceutical company: A European pharmaceutical company required medical, clinical and technical expertise for radoipharmaceuticals, theranostic development and medical imaging. They engaged us to provide the expertise that was not available within the client organization. Our support for a portfolio of molecules spanning Phase I and Phase II clinical trials was critical to the timely execution of the development plan. 

Featured Case Study:
Supporting a PE Fund with Radiopharmaceutical Opportunity Mapping & Market Landscaping


Challenge:

A private equity fund which had successfully invested in the advanced biologics CDMO space was considering entering the radiopharmaceuticals CDMO space through investment in an established European organization. As this was a new area, the fund asked Alacrita to review the European and global markets for radiopharmaceuticals (both imaging agents and therapeutics), characterize the major products on the market and in R&D pipelines and profile the main industry players. A specific request was to quantify the potential market for CDMO services over the coming years which was challenging due to a dearth of published statistics. We were also asked to identify the key success factors in the radiopharma CDMO industry and assess the competitive outlook in the space.

Solution:

We characterized the current and prospective future market for radiopharmaceuticals/diagnostics through our industry knowledge and desk research using subscription and public access databases, the scientific and clinical literature, and company websites, to address: 

  • Current demand for radiopharmaceuticals/diagnostics, segmented by product and indication;
  • Prospective future evolution over the coming 10 years, driven both by existing products and the clinical development pipeline. This included a detailed list of pipeline candidates now and over the past/future by phase of product/company and geographic focus, identifying:
    -    Company sponsor;
    -    Molecule (radionuclide and targeting ligand/chemistry);
    -    Indication;
    -    Development stage;
    -    Estimated launch date.
    -    Addressable market.

We mapped the current (and prospective future) CDMO competitive environment, including:

  • An overview of established CDMOs and recent entrants operating in the radiopharmaceutical space (current capacity and capabilities, strategic partnerships, financial status, other relevant disclosed activities), and of development companies which have, or intend to establish their own GMP capacity;
  • A qualified opinion as to how global pharma involvement in therapeutic and diagnostic radiopharmaceuticals might develop through licensing and acquisition and the implications for future CDMO demand in the US and Europe;
  • Through a combination of desk research and interviews with radiopharma company executives and practicing radiopharmacists, we identified and discussed current issues, drivers and trends. We addressed the internal KSFs required by CDMOs companies which include the issues of technology, internal processes, manufacturing and logistics.

We set this analysis in the context of two potential investment targets, one of which was dropped following presentation of our interim report.